NCI studying gene tests that determine need for chemo

06/12/2006 | NYTimes.com

The National Cancer Institute is conducting trials of a new test that could determine which cancer patients need to receive chemotherapy and which patients may be able to skip the often-harsh treatment. The Oncotype DX test is intended to evaluate the likelihood of relapse in breast cancer patients who have had tumors removed, and researchers want gene tests for colorectal cancer and other malignancies as well.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT